Overview

Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Cephalon
Treatments:
Fentanyl